Sentence examples for inability to validate from inspiring English sources

Nevertheless, these efforts are hampered by the rarity of CUP and the inability to validate the results of such tests due to the paucity of randomized clinical trials.

The uncertainties associated with effective discharge values and the inability to validate effective discharge values as a stream's dominant discharge makes channel design using effective and dominant discharge theory problematic.

If our inability to validate the survey instruments was a limitation of the study, it was forced upon us.

The inability to validate responses is compounded by the fact that fires and sprinkler activations are rare events that yielded small numbers in our final sample.

Second, the method can only validate previously observed associations; consequently, the inability to validate an association does not imply that it is false, it may simply be unknown (see the Discussion section).

Our inability to validate many HLH-1 bound sequences with in vivo assays for enhancer activity, even in the presence of heat shock induced over expression of HLH-1, was also unexpected.

Fourth, the participant self-reported the information, with the inability of the researchers to validate with objective measures the answers and some may overreport socially desirable attitudes and/or behaviors or underreport socially undesirable attitudes and/or behaviors.

Experimental verification and field studies would be necessary to validate the inability for oxidized inorganic N and S utilization by some marine flavobacteria, as suggested by their genome features.

Anonymous ESTs from the microarrays platforms were excluded due to the inability to cross validate the identities between different gene expression profiles.

In DNT test library selection, new approaches are required (Leist et al. 2012a) to break a vicious circle between lack of sufficient tool compounds, and the inability to classically validate test systems without such compounds (Leist et al. 2010, 2012b).

Other hurdles considered moderate included time to analyze and interpret data; inability to prospectively validate safety markers; specialized applications, such as identifying idiosyncratic drug reactions; lack of acceptance of approach by senior management within companies; and concerns of litigation from retrospective analysis.